Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, StockTargetPrices.com reports.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Leerink Swann downgraded Mirna Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $10.00 to $4.00 in a research note on Monday, August 15th. Citigroup Inc. downgraded Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. Zacks Investment Research downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 18th. Finally, HC Wainwright assumed coverage on Mirna Therapeutics in a research report on Monday, September 12th. They set a “buy” rating and a $6.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $7.38.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

Mirna Therapeutics (NASDAQ:MIRN) opened at 2.46 on Wednesday. Mirna Therapeutics has a 12-month low of $2.21 and a 12-month high of $11.01. The stock’s market capitalization is $51.25 million. The stock has a 50 day moving average price of $3.17 and a 200-day moving average price of $4.12.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mirna-therapeutics-inc-mirn-downgraded-by-oppenheimer-holdings-inc.html

A hedge fund recently bought a new stake in Mirna Therapeutics stock. NEA Management Company LLC purchased a new position in shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,974,811 shares of the company’s stock, valued at approximately $18,593,000. Mirna Therapeutics accounts for approximately 1.2% of NEA Management Company LLC’s holdings, making the stock its 16th largest position. Hedge funds and other institutional investors own 30.55% of the company’s stock.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

5 Day Chart for NASDAQ:MIRN

Stock Target Prices

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.